Home / Health / Flu Prevention Breakthrough: 6,000 Patients Enrolled in Trial
Flu Prevention Breakthrough: 6,000 Patients Enrolled in Trial
25 Nov
Summary
- Cidara's CD388 non-vaccine influenza preventative trial has enrolled 6,000 patients.
- The ANCHOR trial is evaluating CD388's efficacy in high-risk populations.
- An interim evaluation is scheduled for the first quarter of 2026.
Cidara Therapeutics has successfully enrolled 6,000 participants in its Phase III ANCHOR trial for CD388, a promising non-vaccine influenza preventative. This significant milestone was achieved across clinical sites in both the UK and the US, ahead of the Northern Hemisphere's peak flu season. The trial aims to evaluate CD388's effectiveness and safety in individuals particularly vulnerable to influenza complications.
The ANCHOR study is a global, double-blind, placebo-controlled trial assessing a single 450mg subcutaneous dose of CD388 in adults and adolescents. Special attention is given to high-risk groups, including immunocompromised patients, those with underlying health conditions, and individuals aged 65 and older. An interim analysis is slated for the first quarter of 2026, which will inform decisions about trial size and potential enrollment adjustments for the Southern Hemisphere.
Positive outcomes from this trial could pave the way for a biologics license application submission for CD388 in these high-risk demographics. Developed using Cidara's Cloudbreak platform, CD388 targets universal influenza prevention by directly inhibiting viral proliferation with a single dose. The therapy previously received Fast Track designation from the FDA in June 2023.
